Tenacia Biotechnologies

Tenacia Biotechnologies is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development and commercialization of innovative therapies for Central Nervous System (CNS) disorders. The company employs a strategic "license-in and co-development" model, partnering with global biotechnology firms to bring advanced CNS treatments to the Greater China market. Its robust pipeline features several late-stage candidates, including lumateperone for schizophrenia and bipolar depression, and fasedienol for social anxiety disorder. Tenacia is backed by a strong consortium of healthcare-focused investors, including 6 Dimensions Capital and Sequoia China. By addressing significant unmet medical needs in psychiatry and neurology, the company aims to become a leader in the rapidly evolving Chinese CNS therapeutic landscape.